Key clinical point:
Major finding: Median overall survival for patients with 0-1, 2-3, and 4 or more factors was 19.6, 5.9, and 2.8 months in the development cohort, and 19.4, 7.2 and 2.6 months in the validation cohort, respectively.
Data source: A study among patients given atezolizumab for advanced urothelial carcinoma with a development cohort (310 patients from the phase 2 IMvigor210 trial) and a validation cohort (95 patients from the phase 1 PCD4989g trial).
Disclosures: Dr. Pond disclosed that an immediate family member is an employee of Roche Canada. Genentech provided data for this study.
Source: Pond GR et al. GU Cancers Symposium Abstract 413
Read the full article.
Pond GR et al. GU Cancers Symposium Abstract 413
This Week's Must Reads
New MOC pathway developed by ABIM, ASCO, Alternative to focus on oncology expertise
Survey indicates opioid prescriptions have decreased , Physicians' progress to reverse the nation's opioid epidemic. American Medical Association.
Oncologists sue over Medicare drug pay cut, Community Oncology Alliance v. Office of Management and Budget et al.
Gender disparity found in oncology research funding, Zhou CD et al. BMJ Open. 2018 Apr 30. doi: 10.1136/bmjopen-2017-018625
Trump administration rejects ACA lawsuit, Texas v. The United States centers on the individual mandate
Must Reads in Renal Cell Carcinoma
Risk categories predict mRCC survival, Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.
Access to care linked to better outcomes in black men with prostate cancer, Halabi et al, George et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology) Abstracts LBA5005 and LBA5009.
Prostate cancer before age 55 more likely in black men, Nettey OS et al. AUA 2018 (American Urological Association annual meeting). Abstract MP 21-17.
Statins may affect prostate cancer microenvironment, Allott E et al. AUA 2018 (annual meeting of the American Urological Association), Abstract MP21-01.
Prostate cancer risks higher in smokers, Foerster B et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1071.